open access

Vol 6, No 4 (2010)
Case report
Published online: 2010-12-16
Get Citation

Mycosis fungoides — a case report

Anna Polakiewicz-Gilowska, Izolda Mrochen-Domin, Elżbieta Nowara
Onkol. Prak. Klin 2010;6(4):195-201.

open access

Vol 6, No 4 (2010)
CASE REPORTS
Published online: 2010-12-16

Abstract

Mycosis fungoides (MF) is the most common type of cutaneous T-cell lymphoma, characterized by an indolent clinical course with subsequent evolution of patches, plagues and tumors. Diagnosis of MF can be difficult due to highly variable presentations.
We present a case of rather rapidly progressive MF in a 64-year-old female who initially presented with psoriasiform patches in context of multidisciplinary approach to this type of disorder.

Onkol. Prak. Klin. 2010; 6, 4: 195–201

Abstract

Mycosis fungoides (MF) is the most common type of cutaneous T-cell lymphoma, characterized by an indolent clinical course with subsequent evolution of patches, plagues and tumors. Diagnosis of MF can be difficult due to highly variable presentations.
We present a case of rather rapidly progressive MF in a 64-year-old female who initially presented with psoriasiform patches in context of multidisciplinary approach to this type of disorder.

Onkol. Prak. Klin. 2010; 6, 4: 195–201

Get Citation

Keywords

mycosis fungoides; radiotherapy; chemotherapy

About this article
Title

Mycosis fungoides — a case report

Journal

Oncology in Clinical Practice

Issue

Vol 6, No 4 (2010)

Article type

Case report

Pages

195-201

Published online

2010-12-16

Bibliographic record

Onkol. Prak. Klin 2010;6(4):195-201.

Keywords

mycosis fungoides
radiotherapy
chemotherapy

Authors

Anna Polakiewicz-Gilowska
Izolda Mrochen-Domin
Elżbieta Nowara

References (40)
  1. Olsen E, Vonderheid E, Pimpinelli N, et al. ISCL/EORTC. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood. 2007; 110(6): 1713–1722.
  2. Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005; 105(10): 3768–3785.
  3. Krajowy Rejestr Nowotworów. http://epid.coi.waw. pl/krn.
  4. Kim YH, Liu HL, Mraz-Gernhard S, et al. Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression. Arch Dermatol. 2003; 139(7): 857–866.
  5. Zackheim HS, Amin S, Kashani-Sabet M, et al. Prognosis in cutaneous T-cell lymphoma by skin stage: long-term survival in 489 patients. J Am Acad Dermatol. 1999; 40(3): 418–425.
  6. van Doorn R, Van Haselen CW, van Voorst Vader PC, et al. Mycosis fungoides: disease evolution and prognosis of 309 Dutch patients. Arch Dermatol. 2000; 136(4): 504–510.
  7. Zackheim HS, Kashani-Sabet M, Amin S. Topical corticosteroids for mycosis fungoides. Experience in 79 patients. Arch Dermatol. 1998; 134(8): 949–954.
  8. Herrmann JJ, Roenigk HH, Hurria A, et al. Treatment of mycosis fungoides with photochemotherapy (PUVA): long-term follow-up. J Am Acad Dermatol. 1995; 33(2 Pt 1): 234–242.
  9. Berthelot C, Rivera A, Duvic M. Skin directed therapy for mycosis fungoides: a review. J Drugs Dermatol. 2008; 7(7): 655–666.
  10. Hoppe R. Mycosis fungoides: radiation therapy. Dermatologic Therapy. 2003; 16(4): 347–354.
  11. Chinn DM, Chow S, Kim YH, et al. Total skin electron beam therapy with or without adjuvant topical nitrogen mustard or nitrogen mustard alone as initial treatment of T2 and T3 mycosis fungoides. Int J Radiat Oncol Biol Phys. 1999; 43(5): 951–958.
  12. Talpur R, Ward S, Apisarnthanarax N, et al. Optimizing bexarotene therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol. 2002; 47(5): 672–684.
  13. Breneman D, Duvic M, Kuzel T, et al. Phase 1 and 2 trial of bexarotene gel for skin-directed treatment of patients with cutaneous T-cell lymphoma. Arch Dermatol. 2002; 138(3): 325–332.
  14. Duvic M, Hymes K, Heald P, et al. Bexarotene Worldwide Study Group. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J Clin Oncol. 2001; 19(9): 2456–2471.
  15. Duvic M, Martin AG, Kim Y, et al. Worldwide Bexarotene Study Group. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Arch Dermatol. 2001; 137(5): 581–593.
  16. Olsen E. Interferon in the treatment of cutaneous T-cell lymphoma. Dermatologic Therapy. 2003; 16(4): 311–321.
  17. Foss FM, Ihde DC, Linnoila IR, et al. Phase II trial of fludarabine phosphate and interferon alfa-2a in advanced mycosis fungoides/Sézary syndrome. J Clin Oncol. 1994; 12(10): 2051–2059.
  18. Olsen EA, Rosen ST, Vollmer RT, et al. Interferon alfa-2a in the treatment of cutaneous T cell lymphoma. J Am Acad Dermatol. 1989; 20(3): 395–407.
  19. Zackheim HS, Kashani-Sabet M, McMillan A. Low-dose methotrexate to treat mycosis fungoides: a retrospective study in 69 patients. J Am Acad Dermatol. 2003; 49(5): 873–878.
  20. Rasheed WK, Johnstone RW, Prince HM. Histone deacetylase inhibitors in cancer therapy. Expert Opin Investig Drugs. 2007; 16(5): 659–678.
  21. Prince HM, Bishton MJ, Harrison SJ. Clinical studies of histone deacetylase inhibitors. Clin Cancer Res. 2009; 15(12): 3958–3969.
  22. Olsen E, Duvic M, Frankel A, et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol. 2001; 19(2): 376–388.
  23. Gardner JM, Evans KG, Musiek A, et al. Update on treatment of cutaneous T-cell lymphoma. Curr Opin Oncol. 2009; 21(2): 131–137.
  24. Prince HM, Whittaker S, Hoppe RT. How I treat mycosis fungoides and Sézary syndrome. Blood. 2009; 114(20): 4337–4353.
  25. Kaye FJ, Bunn PA, Steinberg SM, et al. A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. N Engl J Med. 1989; 321(26): 1784–1790.
  26. Molin L, Thomsen K, Volden G, et al. Combination chemotherapy in the tumour stage of mycosis fungoides with cyclophosphamide, vincristine, vp-16, adriamycin and prednisolone (cop, chop, cavop): a report from the Scandinavian mycosis fungoides study group. Acta Derm Venereol. 1980; 60(6): 542–544.
  27. Akpek G, Koh HK, Bogen S, et al. Chemotherapy with etoposide, vincristine, doxorubicin, bolus cyclophosphamide, and oral prednisone in patients with refractory cutaneous T-cell lymphoma. Cancer. 1999; 86(7): 1368–1376.
  28. Wollina U, Dummer R, Brockmeyer NH, et al. Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma. Cancer. 2003; 98(5): 993–1001.
  29. Scarisbrick JJ, Child FJ, Clift A, et al. A trial of fludarabine and cyclophosphamide combination chemotherapy in the treatment of advanced refractory primary cutaneous T-cell lymphoma. Br J Dermatol. 2001; 144(5): 1010–1015.
  30. Tsimberidou AM, Giles F, Duvic M, et al. Phase II study of pentostatin in advanced T-cell lymphoid malignancies: update of an M.D. Anderson Cancer Center series. Cancer. 2004; 100(2): 342–349.
  31. Zinzani PL, Baliva G, Magagnoli M, et al. Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients. J Clin Oncol. 2000; 18(13): 2603–2606.
  32. Duarte RF, Schmitz N, Servitje O, et al. Haematopoietic stem cell transplantation for patients with primary cutaneous T-cell lymphoma. Bone Marrow Transplant. 2008; 41(7): 597–604.
  33. Piekarz RL, Frye R, Turner M, et al. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol. 2009; 27(32): 5410–5417.
  34. Ellis L, Pan Y, Smyth GK, et al. Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma. Clin Cancer Res. 2008; 14(14): 4500–4510.
  35. Gimsing P. Belinostat: a new broad acting antineoplastic histone deacetylase inhibitor. Expert Opin Investig Drugs. 2009; 18(4): 501–508.
  36. Kim YH, Duvic M, Obitz E, et al. Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma. Blood. 2007; 109(11): 4655–4662.
  37. Enblad G, Hagberg H, Erlanson M, et al. A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. Blood. 2004; 103(8): 2920–2924.
  38. Zinzani PL, Musuraca G, Tani M, et al. Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma. J Clin Oncol. 2007; 25(27): 4293–4297.
  39. Querfeld C, Kuzel TM, Guitart J, et al. Preliminary results of a phase II study of CC-5013 (lenalidomide, Revlimid) in patients with cutaneous T-cell lymphoma. ASH Annual Meeting Abstracts. 2005; 106: Abstract.
  40. O'Connor OA. Pralatrexate: an emerging new agent with activity in T-cell lymphomas. Curr Opin Oncol. 2006; 18(6): 591–597.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl